PolyPid Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PYPD | PLRX | PLRZ | CSBR | PLYX | INO | |
|---|---|---|---|---|---|---|
| Market cap | 118.21M | 52.75M | 27.02M | 67.23M | 89.72M | 167.50M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -5.6 | -0.7 | — | 48.3 | — | -3.9 |
| Price/book | 22.0 | 0.4 | 1.0 | 17.3 | 8.2 | 30.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +44.06% | −47.50% | +96.37% | −28.97% | −95.06% | −27.51% |
| Today | +6.59% | −1.03% | −2.46% | 0.00% | +4.05% | −2.41% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PYPD news ›PolyPid Ltd. (PYPD) Analyst/Investor Day - Slideshow
2026-11-01. The following slide deck was published by PolyPid Ltd. The following slide deck was published by PolyPid Ltd. in conjunction with this event.
PolyPid Unveils Expanded Pipeline Strategy, Introducing PD01B, a New Kynatrix™ Based Product Candidate for the Treatment of Diabetic Foot Infections
Company to host virtual Investor Day today at 11:30 AM ET, featuring key opinion leader Warren S. Joseph, DPM, FIDSA All scheduled FDA interactions on track and aligned with D-PLEX₁₀₀ November 28, 2026 PDUFA goal date PD01B planned to be…
PolyPid rallies after Oppenheimer starts with Outperform rating
As previously reported, Oppenheimer initiated coverage of PolyPid (PYPD) with an Outperform rating and $10 price target The stock in morning tr... PolyPid rallies after Oppenheimer starts with Outperform rating As previously reported,…
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
A new patent application covers Polyrizon’s proprietary mucoadhesive platform and its potential applications in nasal drug delivery. The divisional application, titled “Mucoadhesive Polymers for Nasal Drug Delivery,” was assigned U.S.…
PolyPid spikes as Oppenheimer initiates at Outperform on lead asset
PolyPid (PYPD) stock gains as Oppenheimer launched its coverage of the Israeli biopharma with an Outperform recommendation and a $10 per share target. Read more here. PolyPid (PYPD) shares gained on Tuesday after Oppenheimer launched its…
ChromaDex gets GRAS status for pterostilbene ingredient
A comprehensive review of the safety, toxicology and proposed usage by an independent scientific panel was found to support the GRAS status of the ingredient at an Allowable Daily Intake (ADI) for pTeroPure is up to 30mg/kg (or 1.89 grams)…
PolyPid (NASDAQ:PYPD) Now Covered by Analysts at Oppenheimer
Posted by Sarita Garza on Oct 27th, 2026 Equities researchers at Oppenheimer began coverage on shares of PolyPid (NASDAQ:PYPD – Get Free Report) in a report issued on Tuesday, Briefing.com reports. The brokerage set an “outperform” rating…
PolyPid Ltd Presents Data From SHIELD II Phase 3 Trial Demonstrating Reduced Severity Of Surgical Site Infection
PolyPid Ltd. announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California. The... announced that it will present at the…
Polypid Gains Nda Acceptance and Priority Review for D-Plex100 and Announces Partnership with Azurity Pharmaceuticals
Published on 07/31/2026 at 03:41 pm EDT 18.1%, p=0.0039) and demonstrated a 60% relative risk reduction at the key secondary endpoint measuring surgical site infection incidence (3.8% vs. 9.5%, p=0.0013). A third key secondary showed a 62%…
Azurity Pharmaceuticals Announces Plans To Commercialize D-PLEX100 In The United States And Canada Through Exclusive Partnership With PolyPid
Azurity Pharmaceuticals announced plans to commercialize D-PLEX100 upon approval in the United States and Canada for the prevention of abdominal colorectal surgical site infections in partnership with... Azurity Pharmaceuticals announced…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com12
- markets.businessinsider.com10
- seekingalpha.com3
- stocktitan.net2
- nutraingredients.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 30 articles, not a forecast.